Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 9:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1201–1224 of 3,499 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Protein Control Clear all
Completed Phase 2 Interventional

Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab With and Without Pictilisib in Previously Untreated Advanced or Recurrent Non-small Cell Lung Cancer

NCT01493843
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
pictilisib, Placebo, bevacizumab, carboplatin, paclitaxel
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
44
States / cities
Birmingham, Alabama • Rogers, Arkansas • Encinitas, California + 37 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Oct 31, 2026, 9:57 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Active Preoperative Anemia Management in Patients Undergoing Cardiac Surgery

NCT02189889
View directory record Official record
Conditions
Anemia, Cardiovascular Disease
Interventions
EPO, Feraheme
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 23, 2020 · Synced Oct 31, 2026, 9:57 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Soy Protein on Body Composition and General Health in Healthy Children

NCT02413710
View directory record Official record
Conditions
Generally Healthy Kids Consumption Soy Protein Foods as Part of Daily Diet
Interventions
Soy protein containing foods, Dietary Guidance
Other · Behavioral
Lead sponsor
DuPont Nutrition and Health
Industry
Eligibility
8 Years to 11 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Addison, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 4, 2019 · Synced Oct 31, 2026, 9:57 AM EDT
Terminated Phase 3 Interventional Results available

The Hemophilia Inhibitor Eradication Trial

NCT04303572
View directory record Official record
Conditions
Hemophilia A With Inhibitor
Interventions
Eloctate ITI, Emicizumab
Drug
Lead sponsor
Margaret Ragni
Other
Eligibility
Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Oct 31, 2026, 9:57 AM EDT
Terminated Phase 1Phase 2 Interventional

L-citrulline Injection in Patients Aged 6-21 Years Old with Sickle Cell Disease Presenting with Vaso-Occlusive Crisis (VOC)

NCT04852172
View directory record Official record
Conditions
Acute Vaso Occlusive Crisis (VOC)
Interventions
L-citrulline, D5 1/2NS
Drug · Other
Lead sponsor
Asklepion Pharmaceuticals, LLC
Industry
Eligibility
6 Years to 21 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 31, 2026, 9:57 AM EDT
Terminated Phase 2 Interventional Results available

Nivolumab Combined With BMS-986253 in HCC Patients

NCT04050462
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Nivolumab 240 mg IV every 2 weeks + Cabiralizumab 4 mg/kg IV every 2 weeks, Nivolumab 240 mg IV every 2 weeks + BMS-986253 1200 mg IV every 2 weeks, Nivolumab 240 mg IV every 2 weeks
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
2
States / cities
New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Oct 31, 2026, 9:57 AM EDT
Completed Early Phase 1 Interventional

Effect of Enamel Matrix Proteins on Clinical Attachment Level and Alveolar Bone in Periodontal Maintenance Patients

NCT02972788
View directory record Official record
Conditions
Periodontal Bone Loss
Interventions
Enamel Matrix Proteins Derivative, Saline
Drug · Other
Lead sponsor
University of Nebraska
Other
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 1, 2023 · Synced Oct 31, 2026, 9:57 AM EDT
Completed Not applicable Interventional

Impact of a LCD on Metabolic Inflexibility and Cardiovascular Risk in Liver Transplant Patients

NCT04145427
View directory record Official record
Conditions
Weight Gain
Interventions
Control, LCD
Behavioral
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Oct 31, 2026, 9:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Safety Study to Assess the Effects of Therapeutic and Supratherapeutic Exenatide Concentrations on QT Interval in Healthy Subjects

NCT01297062
View directory record Official record
Conditions
Healthy Subjects
Interventions
Exenatide, Moxifloxacin, Placebo comparator
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
2
States / cities
Daytona Beach, Florida • Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 14, 2015 · Synced Oct 31, 2026, 9:57 AM EDT
Completed Not applicable Interventional

A Study to Assess the Role of a Gluten Free-dairy Free (GFCF) Diet in the Dietary Management of Autism Associated Gastrointestinal Disorders

NCT01116388
View directory record Official record
Conditions
Autism, Gastrointestinal Symptoms
Interventions
GFCF product with GFCF diet, product containing gluten and casein (milk protein) with GFCF diet
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
2 Years to 17 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
2
States / cities
Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 8, 2015 · Synced Oct 31, 2026, 9:57 AM EDT
Completed Not applicable Interventional

Balanced (Egg) Protein During Obesity Reduction: Differential Responses of Insulin Resistance by Race

NCT03771261
View directory record Official record
Conditions
Pre Diabetes, Obesity
Interventions
Weight Loss, Egg Protein
Behavioral · Dietary Supplement
Lead sponsor
Duke University
Other
Eligibility
60 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 11, 2023 · Synced Oct 31, 2026, 9:57 AM EDT
Completed Phase 3 Interventional Results available

Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate

NCT02889796
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Filgotinib, Placebo to match filgotinib, Adalimumab, Placebo to match adalimumab, MTX
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
1,759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
48
States / cities
Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Oct 31, 2026, 9:57 AM EDT
Terminated Phase 3 Interventional Results available

Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine

NCT05028569
View directory record Official record
Conditions
Episodic Migraine
Interventions
BOTOX, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
775 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
82
States / cities
Hoover, Alabama • Huntsville, Alabama • Phoenix, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Oct 31, 2026, 9:57 AM EDT
Terminated Phase 4 Interventional Results available

Botulism Toxin Injection as a Treatment for Arthritis of the Basal Thumb Joint

NCT01045694
View directory record Official record
Conditions
Arthritis Multiple Joint
Interventions
Botulinum Toxin Type A, Steroid - Triamcinolone Acetonide, Lidocaine
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 31, 2026, 9:57 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy, Safety and Tolerability of AG013 in Oral Mucositis Compared to Placebo When Administered Three Times Per Day

NCT03234465
View directory record Official record
Conditions
Oral Mucositis
Interventions
AG013, Placebo
Biological · Other
Lead sponsor
Oragenics, Inc.
Industry
Eligibility
21 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
27
States / cities
Farmington, Connecticut • Newark, Delaware • Orlando, Florida + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Oct 31, 2026, 9:57 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers

A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Weekly Procrit Given to Gastric or Rectal Patients

NCT00254436
View directory record Official record
Conditions
Gastrointestinal Cancer, Rectal Cancer
Interventions
Procrit (epoetin alfa)
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2004
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 25, 2018 · Synced Oct 31, 2026, 9:57 AM EDT
Completed Phase 4 Interventional Results available

Randomized Study of Caspofungin Prophylaxis Followed by Pre-emptive Therapy for Invasive Candidiasis in the Intensive Care Unit (ICU)

NCT00520234
View directory record Official record
Conditions
Invasive Candidiasis
Interventions
Caspofungin, Normal Saline
Drug
Lead sponsor
Mycoses Study Group
Network
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
12
States / cities
Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated May 9, 2011 · Synced Oct 31, 2026, 9:57 AM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Examining the Effect of Acute Intermittent Hypoxia on Serum Blood Proteins and Lower Limb Function

NCT06906536
View directory record Official record
Conditions
INCOMPLETE SPINAL CORD INJURY (ASIA D), Able Bodied
Interventions
Acute Intermittent Hypoxia (AIH)
Other
Lead sponsor
University of Colorado, Boulder
Other
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Boulder, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Oct 31, 2026, 9:57 AM EDT
Completed Phase 3 Interventional Results available

A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors

NCT02847637
View directory record Official record
Conditions
Hemophilia A
Interventions
Emicizumab, Factor VIII (FVIII)
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
12 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
8
States / cities
Santa Monica, California • Washington D.C., District of Columbia • Gainesville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2022 · Synced Oct 31, 2026, 9:57 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19

NCT04649151
View directory record Official record
Conditions
SARS-CoV-2
Interventions
mRNA-1273, Placebo, mRNA-1273.222
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
12 Years to 18 Years
Enrollment
4,328 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
48
States / cities
Banning, California • La Mesa, California • Lake Worth, Florida + 41 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Oct 31, 2026, 9:57 AM EDT
Completed Not applicable Interventional Results available

Optimal VAsopressor titraTION Pilot Randomized Controlled Trial

NCT01800877
View directory record Official record
Conditions
Hypotension, Shock
Interventions
Vasopressors
Drug
Lead sponsor
Francois Lamontagne
Other
Eligibility
17 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 12, 2019 · Synced Oct 31, 2026, 9:57 AM EDT
Withdrawn Phase 3 Interventional

A Study to Evaluate Pharmacokinetics, Safety and Efficacy of Albiglutide in Pediatric Subjects With Type 2 Diabetes Mellitus

NCT03015519
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Albiglutide, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
10 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
3
States / cities
Chicago, Illinois • Morehead City, North Carolina • El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Jan 17, 2019 · Synced Oct 31, 2026, 9:57 AM EDT
Completed Phase 3 Interventional Results available

Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia

NCT00046930
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes
Interventions
filgrastim, sargramostim, cytarabine, daunorubicin hydrochloride, zosuquidar trihydrochloride, Placebo
Biological · Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
60 Years and older
Enrollment
449 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
91
States / cities
Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 67 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2023 · Synced Oct 31, 2026, 9:57 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Oxytocin as Adjunctive Treatment of Schizophrenia

NCT01568528
View directory record Official record
Conditions
Schizophrenia
Interventions
Oxytocin, Placebo, Control
Drug · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 4, 2019 · Synced Oct 31, 2026, 9:57 AM EDT